Welcome to our dedicated page for Cryoport news (Ticker: CYRX), a resource for investors and traders seeking the latest updates and insights on Cryoport stock.
The Cryoport, Inc. (NASDAQ: CYRX) news page on Stock Titan aggregates company announcements, earnings releases, and operational updates related to its role in temperature-controlled supply chain solutions for the life sciences. Cryoport regularly issues news about its performance, infrastructure expansion, and developments across its Life Sciences Services and Life Sciences Products segments.
Recent news has highlighted quarterly financial results, including revenue from continuing operations across Life Sciences Services, BioStorage/BioServices, and Life Sciences Products. The company also reports on metrics such as the number of commercial cell and gene therapies it supports and the global clinical trials that rely on its logistics and storage capabilities.
Operational updates feature the launch and expansion of Global Supply Chain Centers, such as the facility near Paris Charles de Gaulle Airport, which is designed to provide end-to-end, temperature-controlled solutions for biopharma, animal health, and reproductive medicine. Additional news items cover product and technology introductions from MVE Biological Solutions, including dry vapor shippers and integrated condition monitoring systems powered by Tec4med, as well as the MVECloud platform for monitoring cryogenic environments.
Cryoport also publishes news on strategic actions, such as the divestiture of its CRYOPDP specialty courier business and its strategic partnership with DHL, and on quality and compliance milestones, including ISO 21973 certification for transportation of human cells for therapeutic use. Investors and industry observers can use this news feed to follow how Cryoport’s financial performance, infrastructure, and service offerings evolve over time.
Cryoport (NASDAQ: CYRX) has signed an agreement to acquire CRYOPDP, a leading provider of temperature-controlled logistics solutions, for approximately €49 million in cash. This acquisition aims to enhance Cryoport's global supply chain network, particularly in Europe, the Middle East, Africa, and Asia Pacific, regions identified as high-growth areas for biopharma and cell and gene therapies. CRYOPDP reported over €42 million in revenue in 2019 and the acquisition is expected to be immediately accretive to Cryoport's earnings. The deal is anticipated to close within 60 days, subject to standard conditions.
Cryoport (NASDAQ: CYRX) reported Q2 2020 revenues of $9.4 million, an 11% increase year-over-year, driven by its biopharma segment. The company now supports 491 clinical trials, with significant growth in biopharma despite COVID-19 disruptions. Key partnerships remain strong, including renewed agreements with Gilead and FedEx. However, Cryoport posted a net loss of $5.8 million for Q2, up from $2.5 million in 2019. The company holds $208.2 million in cash and investments, bolstered by a convertible debt offering. Future growth is supported by an expanding global supply chain network.
On August 4, 2020, Cryoport (NASDAQ: CYRX) and MEDIPAL HOLDINGS announced a multi-year strategic alliance to provide an integrated supply chain solution for regenerative medicine in Japan. This partnership aims to enhance distribution for specialty cell and gene therapies requiring strict temperature controls and tracking systems. Cryoport supports over 465 clinical trials globally, while MEDIPAL specializes in timely logistics for healthcare products across varied temperatures. The alliance seeks to improve certainty and reduce risks for clients, enabling better service for medical needs.
Cryoport, Inc. (NASDAQ: CYRX) will report its financial results for the second quarter ended June 30, 2020, on August 6, 2020, post-market. An additional review document, highlighting recent financial and operational performance, will be issued concurrently. The management will conduct a conference call at 5:00 PM ET on the same day for investor queries, accessible via their Investor Relations platform.